Cargando…

In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)

Rapid antigen tests (RATs) are an integral part of SARS-CoV-2 containment strategies. As emerging variants of concern (VOCs) displace the initially circulating strains, it is crucial that RATs do not fail to detect these new variants. In this study, four RATs for nasal swab testing were investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungnick, Sabrina, Hobmaier, Bernhard, Mautner, Lena, Hoyos, Mona, Haase, Maren, Baiker, Armin, Lahne, Heidi, Eberle, Ute, Wimmer, Clara, Hepner, Sabrina, Sprenger, Annika, Berger, Carola, Dangel, Alexandra, Ippisch, Siegfried, Hahner, Sonja, Wildner, Manfred, Liebl, Bernhard, Ackermann, Nikolaus, Sing, Andreas, Fingerle, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465346/
https://www.ncbi.nlm.nih.gov/pubmed/34576862
http://dx.doi.org/10.3390/microorganisms9091967
_version_ 1784572849010245632
author Jungnick, Sabrina
Hobmaier, Bernhard
Mautner, Lena
Hoyos, Mona
Haase, Maren
Baiker, Armin
Lahne, Heidi
Eberle, Ute
Wimmer, Clara
Hepner, Sabrina
Sprenger, Annika
Berger, Carola
Dangel, Alexandra
Ippisch, Siegfried
Hahner, Sonja
Wildner, Manfred
Liebl, Bernhard
Ackermann, Nikolaus
Sing, Andreas
Fingerle, Volker
author_facet Jungnick, Sabrina
Hobmaier, Bernhard
Mautner, Lena
Hoyos, Mona
Haase, Maren
Baiker, Armin
Lahne, Heidi
Eberle, Ute
Wimmer, Clara
Hepner, Sabrina
Sprenger, Annika
Berger, Carola
Dangel, Alexandra
Ippisch, Siegfried
Hahner, Sonja
Wildner, Manfred
Liebl, Bernhard
Ackermann, Nikolaus
Sing, Andreas
Fingerle, Volker
author_sort Jungnick, Sabrina
collection PubMed
description Rapid antigen tests (RATs) are an integral part of SARS-CoV-2 containment strategies. As emerging variants of concern (VOCs) displace the initially circulating strains, it is crucial that RATs do not fail to detect these new variants. In this study, four RATs for nasal swab testing were investigated using cultured strains of B.1.1 (non-VOC), B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Based on dilution series in cell culture medium and pooled saliva, the limit of detection of these RATs was determined in a laboratory setting. Further investigations on cross-reactivity were conducted using recombinant N-protein from seasonal human coronaviruses (hCoVs). RATs evaluated showed an overall comparable performance with cultured strains of the non-VOC B.1.1 and the VOCs Alpha, Beta, Gamma, and Delta. No cross-reactivity was detected with recombinant N-protein of the hCoV strains HKU1, OC43, NL63, and 229E. A continuous evaluation of SARS-CoV-2 RAT performance is required, especially with regard to evolving mutations. Moreover, cross-reactivity and interference with pathogens and other substances on the test performance of RATs should be consistently investigated to ensure suitability in the context of SARS-CoV-2 containment.
format Online
Article
Text
id pubmed-8465346
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84653462021-09-27 In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) Jungnick, Sabrina Hobmaier, Bernhard Mautner, Lena Hoyos, Mona Haase, Maren Baiker, Armin Lahne, Heidi Eberle, Ute Wimmer, Clara Hepner, Sabrina Sprenger, Annika Berger, Carola Dangel, Alexandra Ippisch, Siegfried Hahner, Sonja Wildner, Manfred Liebl, Bernhard Ackermann, Nikolaus Sing, Andreas Fingerle, Volker Microorganisms Communication Rapid antigen tests (RATs) are an integral part of SARS-CoV-2 containment strategies. As emerging variants of concern (VOCs) displace the initially circulating strains, it is crucial that RATs do not fail to detect these new variants. In this study, four RATs for nasal swab testing were investigated using cultured strains of B.1.1 (non-VOC), B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Based on dilution series in cell culture medium and pooled saliva, the limit of detection of these RATs was determined in a laboratory setting. Further investigations on cross-reactivity were conducted using recombinant N-protein from seasonal human coronaviruses (hCoVs). RATs evaluated showed an overall comparable performance with cultured strains of the non-VOC B.1.1 and the VOCs Alpha, Beta, Gamma, and Delta. No cross-reactivity was detected with recombinant N-protein of the hCoV strains HKU1, OC43, NL63, and 229E. A continuous evaluation of SARS-CoV-2 RAT performance is required, especially with regard to evolving mutations. Moreover, cross-reactivity and interference with pathogens and other substances on the test performance of RATs should be consistently investigated to ensure suitability in the context of SARS-CoV-2 containment. MDPI 2021-09-16 /pmc/articles/PMC8465346/ /pubmed/34576862 http://dx.doi.org/10.3390/microorganisms9091967 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Jungnick, Sabrina
Hobmaier, Bernhard
Mautner, Lena
Hoyos, Mona
Haase, Maren
Baiker, Armin
Lahne, Heidi
Eberle, Ute
Wimmer, Clara
Hepner, Sabrina
Sprenger, Annika
Berger, Carola
Dangel, Alexandra
Ippisch, Siegfried
Hahner, Sonja
Wildner, Manfred
Liebl, Bernhard
Ackermann, Nikolaus
Sing, Andreas
Fingerle, Volker
In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title_full In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title_fullStr In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title_full_unstemmed In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title_short In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
title_sort in vitro rapid antigen test performance with the sars-cov-2 variants of concern b.1.1.7 (alpha), b.1.351 (beta), p.1 (gamma), and b.1.617.2 (delta)
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465346/
https://www.ncbi.nlm.nih.gov/pubmed/34576862
http://dx.doi.org/10.3390/microorganisms9091967
work_keys_str_mv AT jungnicksabrina invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT hobmaierbernhard invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT mautnerlena invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT hoyosmona invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT haasemaren invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT baikerarmin invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT lahneheidi invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT eberleute invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT wimmerclara invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT hepnersabrina invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT sprengerannika invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT bergercarola invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT dangelalexandra invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT ippischsiegfried invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT hahnersonja invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT wildnermanfred invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT lieblbernhard invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT ackermannnikolaus invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT singandreas invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta
AT fingerlevolker invitrorapidantigentestperformancewiththesarscov2variantsofconcernb117alphab1351betap1gammaandb16172delta